Organization (Nonprofit)
National Bureau of Economic Research
ClinicalTrials.gov lists National Bureau of Economic Research as lead sponsor of 22 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers National Bureau of Economic Research: 22 lead-sponsored trials and 1 legal-entity registration.
Disease areas (16)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Influenza, Human | 6 |
| COVID-19 | 4 |
| Hypertension | 4 |
| Diabetes Mellitus | 3 |
| Acquired Immunodeficiency Syndrome | 2 |
Showing 5 of 16 disease areas.
Trials by start year as sponsor or collaborator (14)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 4 |
| 2021 | 5 |
| 2020 | 4 |
| 2019 | 1 |
| 2016 | 1 |
| 2015 | 3 |
| 2014 | 2 |
Showing 10 of 14 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 2 hit target (n=2) | 3 of 4 on time (n=4) |
Journals published in (15)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| JAMA network open | 4 |
| Annals of internal medicine | 3 |
| The New England journal of medicine | 3 |
| JAMA | 2 |
| Psychological science | 2 |
Showing 5 of 15 journals.
Financing and grant events (106)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-23 | NIH grant | 3,121,921 | Reporter |
| 2025-09-12 | NIH grant | 643,697 | Reporter |
| 2025-09-04 | NIH grant | 782,986 | Reporter |
| 2025-08-21 | NIH grant | 736,672 | Reporter |
| 2025-08-18 | NIH grant | 2,906,646 | Reporter |
Showing 5 of 106 events.
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| Harvard School of Public Health (HSPH) | Co sponsors trial with | 1 |
Latest dated events (139)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-04-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09-23 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-09-12 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-09-04 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-08-21 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 139 events.
Biomarker capability evidence (2)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| INSRR | Trial sponsor | Mentioned in trial text |
| MPL | Trial sponsor | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, us granted patents, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.